|
1.
|
Irby RB and Yeatman TJ: Role of Src
expression and activation in human cancer. Oncogene. 19:5636–5642.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Stettner MR, Wang W, Nabors LB, et al: Lyn
kinase activity is the predominant cellular SRC kinase activity in
glioblastoma tumor cells. Cancer Res. 65:5535–5543. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Ding Q, Stewart J Jr, Prince CW, et al:
Promotion of malignant astrocytoma cell migration by osteopontin
expressed in the normal brain: differences in integrin signaling
during cell adhesion to osteopontin versus vitronectin. Cancer Res.
62:5336–5343. 2002.
|
|
4.
|
Summy JM and Gallick GE: Src family
kinases in tumor progression and metastasis. Cancer Metastasis Rev.
22:337–358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Frame MC: Src in cancer: deregulation and
consequences for cell behaviour. Biochim Biophys Acta.
1602:114–130. 2003.PubMed/NCBI
|
|
6.
|
Yamaguchi H and Hendrickson WA: Structural
basis for activation of human lymphocyte kinase Lck upon tyrosine
phosphorylation. Nature. 384:484–489. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Guarino M: Src signaling in cancer
invasion. J Cell Physiol. 223:14–26. 2010.
|
|
8.
|
Lu KV, Zhu S, Cvrljevic A, et al: Fyn and
SRC are effectors of oncogenic epidermal growth factor receptor
signaling in glioblastoma patients. Cancer Res. 69:6889–6898. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Lund CV, Nguyen MT, Owens GC, Pakchoian
AJ, Shaterian A, Kruse CA and Eliceiri BP: Reduced glioma
infiltration in Src-deficient mice. J Neurooncol. 78:19–29. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Summy JM and Gallick GE: Treatment for
advanced tumors: SRC reclaims center stage. Clin Cancer Res.
12:1398–1401. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Yeatman TJ: A renaissance for SRC. Nat Rev
Cancer. 4:470–480. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Takeya T and Hanafusa H: DNA sequence of
the viral and cellular src gene of chickens. II. Comparison of the
src genes of two strains of avian sarcoma virus and of the cellular
homolog. J Virol. 44:12–18. 1982.PubMed/NCBI
|
|
13.
|
Jove R and Hanafusa H: Cell transformation
by the viral src oncogene. Annu Rev Cell Biol. 3:31–56. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Weissenberger J, Steinbach JP, Malin G,
Spada S, Rulicke T and Aguzzi A: Development and malignant
progression of astrocytomas in GFAP-v-src transgenic mice.
Oncogene. 14:2005–2013. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
de Groot J and Milano V: Improving the
prognosis for patients with glioblastoma: the rationale for
targeting Src. J Neurooncol. 95:151–163. 2009.PubMed/NCBI
|
|
16.
|
Dey N, Crosswell HE, De P, Parsons R, Peng
Q, Su JD and Durden DL: The protein phosphatase activity of PTEN
regulates SRC family kinases and controls glioma migration. Cancer
Res. 68:1862–1871. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Sikkema AH, Diks SH, den Dunnen WF, et al:
Kinome profiling in pediatric brain tumors as a new approach for
target discovery. Cancer Res. 69:5987–5995. 2009. View Article : Google Scholar
|
|
18.
|
Du J, Bernasconi P, Clauser KR, et al:
Bead-based profiling of tyrosine kinase phosphorylation identifies
SRC as a potential target for glioblastoma therapy. Nat Biotechnol.
27:77–83. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Nomura N, Nomura M, Sugiyama K and Hamada
J: Src regulates phorbol 12-myristate 13-acetate-activated
PKC-induced migration via Cas/Crk/Rac1 signaling pathway in
glioblastoma cells. Int J Mol Med. 20:511–519. 2007.
|
|
20.
|
Bao S1, Wu Q, McLendon RE, et al: Glioma
stem cells promote radioresistance by preferential activation of
the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Liu G, Yuan X, Zeng Z, et al: Analysis of
gene expression and chemoresistance of CD133+cancer stem
cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Friedman GK, Langford CP, Coleman JM,
Cassady KA, Parker JN, Markert JM and Yancey Gillespie G:
Engineered herpes simplex viruses efficiently infect and kill
CD133+human glioma xenograft cells that express CD111. J
Neurooncol. 95:199–209. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Lin T, Islam O and Heese K: ABC
transporters, neural stem cells and neurogenesis - a different
perspective. Cell Res. 16:857–871. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Bradeen HA, Eide CA, O’Hare T, et al:
Comparison of imatinib mesylate, dasatinib (BMS-354825), and
nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based
mutagenesis screen: high efficacy of drug combinations. Blood.
108:2332–2338. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Milano V, Piao Y, LaFortune T and de Groot
J: Dasatinib-induced autophagy is enhanced in combination with
temozolomide in glioma. Mol Cancer Ther. 8:394–406. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Fael Al-Mayhani TM, Ball SL, Zhao JW,
Fawcett J, Ichimura K, Collins PV and Watts C: An efficient method
for derivation and propagation of glioblastoma cell lines that
conserves the molecular profile of their original tumours. J
Neurosci Methods. 176:192–199. 2009.PubMed/NCBI
|
|
27.
|
Pollard SM, Yoshikawa K, Clarke ID, et al:
Glioma stem cell lines expanded in adherent culture have
tumor-specific phenotypes and are suitable for chemical and genetic
screens. Cell Stem Cell. 4:568–580. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Boivin D, Labbé D, Fontaine N, Lamy S,
Beaulieu E, Gingras D and Béliveau R: The stem cell marker CD133
(prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and
tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry.
48:3998–4007. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Kim RK, Yoon CH, Hyun KH, et al: Role of
lymphocyte-specific protein tyrosine kinase (LCK) in the expansion
of glioma-initiating cells by fractionated radiation. Biochem
Biophys Res Commun. 402:631–636. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Burgess MR, Skaggs BJ, Shah NP, Lee FY and
Sawyers CL: Comparative analysis of two clinically active BCR-ABL
kinase inhibitors reveals the role of conformation-specific binding
in resistance. Proc Natl Acad Sci USA. 102:3395–3400. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Lombardo LJ, Lee FY, Chen P, et al:
Discovery of
N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
(BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor
activity in preclinical assays. J Med Chem. 47:6658–6661. 2004.
View Article : Google Scholar
|
|
32.
|
Shah NP, Tran C, Lee FY, Chen P, Norris D
and Sawyers CL: Overriding imatinib resistance with a novel ABL
kinase inhibitor. Science. 305:399–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Hermanson M, Funa K, Hartman M,
Claesson-Welsh L, Heldin CH, Westermark B and Nistér M:
Platelet-derived growth factor and its receptors in human glioma
tissue: expression of messenger RNA and protein suggests the
presence of autocrine and paracrine loops. Cancer Res.
52:3213–3219. 1992.
|
|
34.
|
Haberler C, Gelpi E, Marosi C, Rössler K,
Birner P, Budka H and Hainfellner JA: Immunohistochemical analysis
of platelet-derived growth factor receptor-alpha, -beta, c-kit,
c-abl, and arg proteins in glioblastoma: possible implications for
patient selection for imatinib mesylate therapy. J Neurooncol.
76:105–109. 2006. View Article : Google Scholar
|
|
35.
|
Wang LF, Fokas E, Bieker M, et al:
Increased expression of EphA2 correlates with adverse outcome in
primary and recurrent glioblastoma multiforme patients. Oncol Rep.
19:151–156. 2008.PubMed/NCBI
|
|
36.
|
Wykosky J, Gibo DM, Stanton C and Debinski
W: EphA2 as a novel molecular marker and target in glioblastoma
multiforme. Mol Cancer Res. 3:541–551. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Porkka K, Koskenvesa P, Lundán T, et al:
Dasatinib crosses the blood-brain barrier and is an efficient
therapy for central nervous system Philadelphia chromosome-positive
leukemia. Blood. 112:1005–1012. 2008. View Article : Google Scholar
|
|
38.
|
Gilbertson RJ and Rich JN: Making a
tumour’s bed: glioblastoma stem cells and the vascular niche. Nat
Rev Cancer. 7:733–736. 2007.
|
|
39.
|
Shen Q, Wang Y, Kokovay E, et al: Adult
SVZ stem cells lie in a vascular niche: a quantitative analysis of
niche cell-cell interactions. Cell Stem Cell. 3:289–300. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Lathia JD, Gallagher J, Heddleston JM, et
al: Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem
Cell. 6:421–432. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Lee J, Kotliarova S, Kotliarov Y, et al:
Tumor stem cells derived from glioblastomas cultured in bFGF and
EGF more closely mirror the phenotype and genotype of primary
tumors than do serum-cultured cell lines. Cancer Cell. 9:391–403.
2006. View Article : Google Scholar : PubMed/NCBI
|
